SCHEMBL3209853

SCHEMBL3209853

COc1cccc(OC)c1Cc1cc2cc(F)ccc2nc1N

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 2/20 0.42
BACE1 P56817 2/20 0.39
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
PDGFRB P09619 2/20 0.39
PDGFRA P16234 2/20 0.39
PLA2G2A P14555 1/20 0.38
MEN1 O00255 1/20 0.38
RAD52 P43351 1/20 0.38
KMT2A Q03164 1/20 0.38
DCPS Q96C86 2/20 0.38
AMY1A P0DUB6 1/20 0.38
KCNH2 Q12809 1/20 0.37
PKM P14618 1/20 0.37
DHPS P49366 1/20 0.36
DHFR P00374 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3197519 0.94 TLR8 (0.40) TLR8BACE1TP53POLBMAPT
SCHEMBL3219290 0.87 PLA2G2A (0.48) TLR8BACE1MAPTPLA2G2AMEN1
SCHEMBL3210074 0.86 TLR8 (0.41) TLR8POLBPDGFRBPDGFRAMEN1
SCHEMBL3206611 0.85 TLR8 (0.60) TLR8MEN1KMT2ADCPS
SCHEMBL3219124 0.85 KDM4E (0.47) TLR8TP53MAPTPDGFRBPDGFRA
SCHEMBL3215454 0.84 TLR8 (0.40) TLR8TP53POLBMAPTPLA2G2A
SCHEMBL3210319 0.83 DPP4 (0.39) TLR8POLBMAPTPDGFRBPDGFRA
SCHEMBL3222731 0.83 PDE10A (0.46) TLR8TP53DHFR
SCHEMBL3197974 0.82 TLR8 (0.54) TLR8MEN1KMT2ADCPSDHFR
SCHEMBL3215144 0.81 PDE10A (0.42) TLR8DCPSDHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221371-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-08-07 US disclosed
US-20100041698-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2010-02-18 US disclosed
EP-1917245-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS Abbott GmbH & Co. KG (DE) 2008-05-07 EP disclosed
WO-2007022946-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS ABBOTT GMBH & CO. KG (DE) 2007-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221371-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS HTR5A, HTR1A, HTR2C TLR8 3013/4885BACE1 280/4885TP53 3150/4885
US-20100041698-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS HTR5A, HTR1A, HTR2C TLR8 3013/4885BACE1 280/4885TP53 3150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.